Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion
XX min read
TL;DR
Oops! Something went wrong while submitting the form.
Share on Social
More media
December 9, 2025
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies
Announcement
December 9, 2025
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies
Announcement